Nebivolol: a review

Bibliography

• STAESSEN J, WANG J-G, THUS L:Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. Hypertension (2003) 21:1055–1076.
   Web of Science ®Google Scholar
• TURNBULL F, BLOOD PRESSURE LOWERING TREATMENT TRIALIST'S COLLABORATION: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 362:1527–1535.
   PubMed Web of Science ®Google Scholar
• WILKINSON IB, QASEM A, MCENIERY CM, WEBB DJ, AVOLIO AP, COCKCROFT JR: Nitric oxide regulates local arterial distensibility in vivo. Circulation (2002) 105:213–217.
   Google Scholar
• ••The first study to show that endothelium-derived NO is involved in the regulation of large arterial stiffness.
   Google Scholar
• KINLAY S, CREAGER MA, FUKUMOTO M et al.: Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension (2001) 38:1049–1053.
   PubMed Web of Science ®Google Scholar
• COCKCROFT JR, CHOWIENCZYK PJ, BRETT SE et al.: Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. .1. Pharmacol Exp. Ther. (1995) 274:1067–1071.
   Google Scholar
• ••The very first study to demonstrate thatnebivolol causes vasodilatation in a human vascular bed via the release of NO.
   Google Scholar
• CLEOPHAS TJ, VAN OUWERKERK B, VAN DER MEULEN J: Nebivolol, a third generation novel beta-blocker, systematic review. J. Am. Coll. Ang. (2003) 1:101–113.
   Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L, SALVETTI A: The role of endothelium in human hypertension. Curt: Opin. Nephrol. Hypertens. (1996) 7:203–209.
   Web of Science ®Google Scholar
• TZEMOS N, LIM PO, MACDONALD TM: Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation (2001) 104:511–514.
   PubMed Web of Science ®Google Scholar
• ••The first study to demonstrate thatnebivolol given orally at clinical doses improves endothelial function in patients with hypertension.
   Google Scholar
• VAN MERODE T, VAN BORTEL LMAB, SMEETS FA: Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients.' Hypertens. (1989) 7(Suppl.):S262–S263.
   Google Scholar
• UHLIR 0, FEJIFUSA M, HAVRANEK K: Nebivolol versus metoprolol in the treatment of hypertension. Drug Investigation (1991) 3\(Suppl. 1):107–110.
   Google Scholar
• DE CREE J, GEUKENS H, VERHAEGEN H: Non-invasive cardiac haemodynamics of nebivolol. Drug Investigation (1991) 3\(Suppl. 1):25–30.
   Google Scholar
• STOLERU L, WIJNS W, VAN EYLL C, BOUVY T, VAN NUETEN L, POULEUR H: Effects of d-nebivolol and 1-nebivolol on left ventricular systolic and diastolic function: comparison with dl-nebivolol and atenolol. Cardiovasc. Pharmacol (1993) 22:183–190.
   PubMed Web of Science ®Google Scholar
• ROBERTSON JIS, BALL SG: Hypertension for the clinician. Robertson JIS, Ball SG (Eds), WB Saunders, London, UK (1994) ISBN: 0702018120.
   Google Scholar
• MONCADA S: Nitric oxide. .1. Hypertens. (1994) 12\(Suppl. 10):35–39.
   Google Scholar
• VAN BORTEL L MAB, DE HOON JNJM, KOOL MJ, WIJNEN JA, VERTOMMEN C, VAN NUETEN L: Pharmacological properties of nebivolol in man. Eur. Pharmacol (1997) 51:379–384.
   Web of Science ®Google Scholar
• CLEOPHAS T J: Experimental evidence of selective antagonistic action of nebivolol on beta-1 adrenergic receptors. J. Clin. Med. (1998) 2:2–8.
   Google Scholar
• VAN NUETEN L, DE CREE J: Nebivolol: a comparison of the effects of dl-nebivolol, d-nebivolol, 1-nebivolol, atenolol, placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc. Drugs Ther. (1998) 12:339–344.
   PubMed Web of Science ®Google Scholar
• VAN PEER A, SNOECK E, WOESTENBORGHS R: Clinical pharmacokinetics of nebivolol: a review. Drug Investigation (1991) 3\(Suppl. 1):25–30.
   Google Scholar
• HIMMELMAN A, HEDNER T, SNOECK E: Haemodynamic effects and pharmacokinetics of oral d- and 1-nebivolol in hypertensive patients. Eur. I Clin. Pharmacol (1996) 51:259–264.
   PubMed Web of Science ®Google Scholar
• MONCADA S, HIGGS A: The L-arginine-nitric oxide pathway. N Engl I Med. (1993) 329:2202–2012.
   Web of Science ®Google Scholar
• PANZA JA, CASINO PR, KILCOYNE CM, QUYYUMI AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation with essential hypertension. Circulation (1993) 87:1468–1474.
   PubMed Web of Science ®Google Scholar
• SHIMOKAWA H: Endothelial dysfunction in hypertension. Atheroscler. Thromb. (1998) 4:118–127.
   Google Scholar
• NAPOLI C, LIGUORI A, DE NIGRIS F: Beneficial effects of nebivolol on the NO-pathway in essential hypertensive patients. Eur. Heart I (2002) 23\(Suppl. 1):210 (Abstract).
   Google Scholar
• GAO Y, NAGAO T, BOND RA, JANSSENS WJ, VANHOUTTE P: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Cardiovasc. Pharmacol (1991) 17:964–969.
   PubMed Web of Science ®Google Scholar
• DAWES M, BRETT SE, CHOWIENCZYK PJ, MANT TGK, RITTER JM: The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Gin. Pharmacol (1999) 48:460–463.
   Web of Science ®Google Scholar
• •The first study to demonstrate that nebivolol produced endothelium-dependent dilatation in subjects with hypertension.
   Google Scholar
• BOWMAN AJ, CHEN CP-H, FORD GA: Nitric oxide mediated venodilator effects of nebivolol. Br. Clin. Pharmacol (1994) 38:199–204.
   PubMed Web of Science ®Google Scholar
• RITTER JM: Nebivolol: endothelium-mediated vasodilating effect. Cardiovasc. Pharmacol (2001) 38\(Suppl. 3):513–516.
   Google Scholar
• VAN DE WATER A, JANSSENS WJ, VAN NUETEN L et al: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective betal-adrenergic antagonist. Cardiovasc. Pharmacol (1988) 11:552–563.
   PubMed Web of Science ®Google Scholar
• VAN BORTEL L MAB, BREED JGS et al:Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. Cardiovasc. Pharmacol (1993) 21:856–862.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, DUPONT AG, VERTOMMEN C, GOYVAERTS H, ROBERTSON JIS: A dose-response trial of nebivolol in essential hypertension. j. Hum. Hypertens. (1997) 11:139–144.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, SCHELLING A, VERTOMMEN C, DUPONT AG, ROBERTSON JIS: Nebivolol versus enalapril in the treatment of essential hypertension: a double-blind randomised trial. Hum. Hypertens. (1997) 11:813–819.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, LACOURCIERE Y, VYSSOULIS G et al.: Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind randomised comparative trial. Am. Ther. (1998) 5:237–243.
   PubMedGoogle Scholar
• VAN NUETEN L, TAYLOR FR, ROBERTSON JIS: Nebivolol versus atenolol and placebo in essential hypertension: a double-blind randomised trial. Hum. Hypertens. (1998) 12:135–140.
   PubMed Web of Science ®Google Scholar
• KAMP 0, SIESWERDA GT, VISSER CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. Cardiol (2003) 92:344–348.
   PubMed Web of Science ®Google Scholar
• •The first study to demonstrate beneficial efects of nebivolol on cardiac function in patients with essential hypertension.
   Google Scholar
• VAN BORTEL L MAB, VAN BAAK MA: Exercise tolerance with nebivolol and atenolol. Cardiovasc. Drugs Ther. (1992) 6:239–247.
   PubMed Web of Science ®Google Scholar
• MAZZA A, GIL-EXTREMERA B, MALDONATO A, TOUTOUZAS T, PESSINA C: Nebivolol versus amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. (2002) 11:182–188.
   PubMed Web of Science ®Google Scholar
• UKPDS GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes (UKPDS 38). Br. Med. J. (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, WILSON PW, ZHANG TJ: The epidemiology of impaired glucose tolerance and hypertension. Am. Heart J. (1991) 121:1268–1273.
   PubMed Web of Science ®Google Scholar
• FOGARI R, ZOPPI A, LAZZARI P et al: Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive patients with Type II diabetes. Hum. Hypertens. (1997) 11:753–757.
   PubMed Web of Science ®Google Scholar
• CLEOPHAS TJ, GRABOWSKY I, NIEMEYER MG, MAKEL WN, VAN DER WALL EE: Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr. Ther. Res. (2001) 62:451–461.
   Web of Science ®Google Scholar
• FALLOIS JV, FAULHABER H-D: Nebivolol, a third generation beta blocker: the current treatment of arterial hypertension. Praxis (2001) 90:435–441.
   PubMedGoogle Scholar
• LACOURCIERE Y, ARNOTT W: Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J. Hum. Hypertens. (1994) 8:283–288.
   PubMed Web of Science ®Google Scholar
• BENETOS A, SAFAR M, RUDNICHI A et al.: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension (1997) 30:1410–1415.
   PubMed Web of Science ®Google Scholar
• BENETOS A, RUDNICHI A, SAFAR M,GUIZE L: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension (1998) 32:560–564.
   PubMed Web of Science ®Google Scholar
• MITCHELL GE MOYE LA, BRAUNWALD E et al: Sphygomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation (1997) 96:4254–4260.
   PubMed Web of Science ®Google Scholar
• MILLAR JA, LEVER AF, BURKE V: Pulsepressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J. Hypertens. (1999) 17:1065–1072.
   PubMed Web of Science ®Google Scholar
• BLACHER J, STAESSEN J, GIRERD Xet al.: Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. (2000) 160:1085–1089.
   Google Scholar
• BOUTOUYRIE P, TROPEANO Al, ASMAR R et al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension (2002) 39:10–15.
   PubMed Web of Science ®Google Scholar
• CRUICKSHANK K, RISTE L, ANDERSON SG, WRIGHT JS, DUNN G, GOSLING RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function? Circulation (2002) 106:2085–2090.
   Google Scholar
• BLACHER J, GUERIN AP, PANNIER B, MARCHAIS S J, SAFAR M, LONDON GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation (1999) 99:2434–2439.
   PubMed Web of Science ®Google Scholar
• •A seminal study demonstrating that aortic stiffness predicts survival.
   Google Scholar
• MEAUME S, BENETOS A, HENRY OF, RUDNICHI A, SAFAR M: Aortic pulse wave velocity predicts cardiovascular mortality in subjects 70 years of age. Arterioscier. a/MA 16SC. Biol. (2001) 21:2046–2050.
   PubMed Web of Science ®Google Scholar
• COCKCROFT JR, WILKINSON IB, WEBB DJ: The Trevor Howell Lecture: age, arterial stiffness and the endothelium. Ageing (1997) 26:53–60.
   Google Scholar
• CHEN CP-H, TING C-T, LIN S-J et al:Different effects of fosinipril and atenolol on wave reflection in hypertensive patients. Hypertension (1995) 25:1034–1041.
   PubMed Web of Science ®Google Scholar
• VAN BORTEL LMAB, KOOL MJ, BOUDIER HA, STRUIJKER HA: Effects of antihypertensive agents on local arterial distensibility and compliance. Hypertension (1995) 26:531–534.
   PubMed Web of Science ®Google Scholar
• •An important study comparing the effects of different antihypertensive agents on arterial stiffness.
   Google Scholar
• BREITHAUPT-GROGLER K, LESCHINGER M, BELZ GG et al: Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc. Drugs Ther. (1996) 10:49–57.
   PubMed Web of Science ®Google Scholar
• DREARY AJ, SCHUMANN AL, MURFET H, HAYDOCK S, FOO RS, BROWN MJ: Influence of drugs and gender on the arterial pulse wave andnatiuretic peptide secretion in untreated patients with essential hypertension. Gin. Sri. (2002) 103:493–499.
   Google Scholar
• TING C-T, YANG T-M, CHEN J-W, CHANG M-S, YIN F C P: Arterial hemodynamics in human hypertension: effects of angiotensin converting enzyme inhibition. Hypertension (1993) 22:839–846.
   PubMed Web of Science ®Google Scholar
• O'ROURKE ME KELLY RP, AVOLIO AP, HAYWARD C: Effects of arterial dilator agents on central systolic pressure and on left ventricular hydraulic load. Am.j Cardiol (1989) 63:381–441.
   Web of Science ®Google Scholar
• NICHOLS WW, O'ROURKE MF: McDonalds Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles (1998).
   Google Scholar
• MCENIERY CM, WILKINSON IB, QASEM A, AVOLIO AP, WEBB DJ, COCKCROFT JR: Nitric oxide regulates large artery stiffness in vivo. Br. J. Clin. Pharmacol (2002) 53:426P
   Web of Science ®Google Scholar
• STEINER SS, FRIEDHOFF AJ, WILSON BL, WECKER JR, SANTO JP: Antihypertensive therapy and quality of life: comparison of atenolol, enalapril and propanolol. Hum. Hypertens. (1990) 4:217–225.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, LEFEBVRE J, POIRIER L: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomised, double-blind, placebo-controlled, factorial-design trial. Am. Hypertens. (1994) 7:137–145.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, POIRIER L, LEFEBVRE J: Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J. Clin. Pharmacol (1992) 32:660–666.
   PubMed Web of Science ®Google Scholar
• CRUICKSHANK JM, PRICHARD BNC:Beta-blockers in clinical practice. Cruickshank JM, Prichard BNC (Eds), Churchill Livingstone, Edinburgh, UK (1987) ISBN: 0443029881.
   Google Scholar